Acute heart failure treatment

Critical Pathways in Cardiology

Volumn 7, Issue 2, 2008, Pages 103-110

  Kirk, J Douglas ^a   Filippatos, Gerasimos ^a   Gheorghiade, Mihai ^a   Pang, Peter S ^a   Levy, Phillip ^a   Amsterdam, Ezra A ^a   Peacock, W Frank ^a   Fonarow, Gregg C ^a  

^a Society of Chest Pain Centers   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPTOPRIL; ENALAPRILAT; FUROSEMIDE; ISOSORBIDE DINITRATE; MORPHINE SULFATE; NESIRITIDE; NITRATE; NITROPRUSSIDE SODIUM; PLACEBO;

ABDOMINAL PAIN; ACUTE HEART FAILURE; ADRENALIN BLOOD LEVEL; ALDOSTERONE BLOOD LEVEL; ANAMNESIS; ARTIFICIAL VENTILATION; CARDIAC PATIENT; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; DISEASE CLASSIFICATION; DIURESIS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; DYSPNEA; EMERGENCY CARE; ENDOTRACHEAL INTUBATION; EVALUATION; FATIGUE; HEADACHE; HEART EJECTION FRACTION; HEART INFARCTION; HEART LEFT VENTRICLE FILLING PRESSURE; HEART OUTPUT; HUMAN; HYPOTENSION; KIDNEY DISEASE; KIDNEY FUNCTION; LOADING DRUG DOSE; LOW DRUG DOSE; LUNG CONGESTION; LUNG EDEMA; OXYGEN THERAPY; PATIENT CODING; PERIPHERAL EDEMA; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; PULMONARY ARTERY OCCLUSION PRESSURE; REPEATED DRUG DOSE; REVIEW; SIDE EFFECT; SYSTEMIC VASCULAR RESISTANCE; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; VEIN DILATATION; WEIGHT GAIN;

EID: 67650118200     PISSN: 1535282X     EISSN: 15352811     Source Type: Journal    
DOI: 10.1097/HPC.0b013e318177df37     Document Type: Review

References (63)

1. Gheorghiade M, De Luca L, Fonarow GC, et al. Pathophysiologic targets in the early phase of acute heart failure syndromes. Am J Cardiol. 2005;96(suppl 6A):11G-17G.
2. Gheorghiade M, Zannad F, Sopko G, et al. Acute heart failure syndromes: current state and framework for future research. Circulation.2005;112: 3958-3968.
3. Cotter G, Moshkovitz Y, Milovanov O, et al. Acute heart failure: a novel approach to its pathogenesis and treatment. Eur J Heart Fail. 2002;4:227-234.
4. Adams KF Jr, Fonarow GC, Emerman CL, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States:rationale, design, and preliminary observations from the first 100,000cases in the Acute Decompensated Heart Failure National Registry(ADHERE). Am Heart J. 2005;149:209-216.
5. Cleland JG, Swedberg K, Follath F, et al. The EuroHeart Failure survey programme-a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. EurHeart J. 2003;24:442-463.
6. Adams KF, Lindenfeld J, Arnold JMO, et al. For the Heart Failure Society of America. HFSA 2006 comprehensive heart failure practiceguideline. J Card Fail. 2006;12:e121-e122.
7. Nieminen MS, Bohm M, Cowie MR, et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the task force on acute heart failure of the European Society of Cardiology. Eur Heart J. 2005;26:384-416.
8. Gheorghiade M, Mebazaa A. Introduction to acute heart failure syn dromes. Am J Cardiol. 2005;96(suppl 6A):1G-4G.
9. Bayram M, De Luca L, Massie MB, et al. Reassessment of dobutamine,dopamine, and milrinone in the management of acute heart failure syndromes. Am JCardiol. 2005;96(suppl):47G-58G.
10. BraterDC. Diuretic therapy. N Engl J Med. 1998;339:387-395.
11. Stough WG, O'Connor CM, Gheorghiade M. Overview of current noninodilator therapies for acute heart failure syndromes. Am JCardiol.2005;96(suppl): 41G-46G.
12. Moazemi K, Chana JS, Willard AM, et al. Intravenous vasodilator therapy in congestive heart failure. Drugs Aging. 2003;20:485-508.
13. Elkayam U, Bitar F, Akhter MW, et al. Intravenous nitroglycerin in the treatment of decompensated heart failure: potential benefits and limitations. JCardiovasc Pharmacol Ther. 2004;9:227-241.
14. Gottlieb SS, Brater DC, Thomas I, et al. BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation. 2002;105:1348 -1353.
15. Jhund PS, McMurray J, Davie AP. The acute vascular effects of furosemide in heart failure. Br JClin Pharmacol. 2000;50:9-13.
16. Weinfeld MS, Chertow GM, Stevenson LW. Aggravated renal dysfunction during intensive therapy for advanced chronic heart failure. Am Heart J. 1999;138:285-290.
17. Cooper HA, Dries DL, Davis CE, et al. Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation. 1999;100:1311-1315.
18. Lahav M, Regev A, Ra'anani P. Intermittent administration of furo semide vs continuous infusion preceded by a loading dose for congestive heart failure. Chest. 1992;102:725-731.
19. Dormans TP, van Meyel JJ, Gerlag PG, et al. Diuretic efficacy of high dose furosemide in severe heart failure: bolus injection versus continu ous infusion. J Am Coll Cardiol. 1996;28:376 -382.
20. Cotter G, Weissgarten J, Metzkor E, et al. Increased toxicity of high dose furosemide versus low-dose dopamine in the treatment of refractory congestive heart failure. Clin Pharmacol Ther. 1997;62:187-193.
21. Cotter G, Metzkor E, Kaluski E, et al. Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furo-semide plus low-dose isosorbide dinitrate in severe pulmonary oedema.Lancet. 1998;351:389-393.
22. Heywood JT. Temporal characteristics of serum creatinine elevations inpatients receiving nesiritide and nitroglycerin. Presented at: Heart Failure Society of America 9th Annual Scientific Sessions; September 20,2005; Boca Raton, FL. Abstract 255.
23. Burger AJ. Clinical predictors of worsening renal function in patients hospitalized for heart failure. Presented at: Heart Failure Society of America 9th Annual Scientific Sessions; September 19, 2005; BocaRaton, FL. Abstract 345.
24. Elkayam U, Roth A, Kumar A, et al. Hemodynamic and volumetric effects of venodilation with nitroglycerin in chronic mitral regurgitation.Am J Cardiol. 1987;60:1106-1111.
25. Loh E, Elkayam U, Cody R, et al. A randomized multicenter study comparing the efficacy and safety of intravenous milrinone and intravenous nitroglycerin in patients with advanced heart failure. J Card Fail.2001;7:114-121.
26. Nashed AH, Allegra JR. Intravenous nitroglycerin boluses in treating patients with cardiogenic pulmonary edema. Am J Emerg Med. 1995;13:612-613.
27. Nashed AH, Allegra JR, Eskin B, et al. Prospective trial of the treatment of acute cardiogenic pulmonary edema with IV nitroglycerin boluses.Ann Emerg Med. 1997;30:382.
28. Cotter G, Faibel H, Barash P, et al. High-dose nitrates in the immediate management ofunstable angina: optimal dosage, route ofadministration,and therapeutic goals. Am JEmerg Med. 1998;16:219 -224.
29. Levy P, Hexdall A, Gordon P, et al. A randomized trial of bolus nitroglycerin for the treatment of acute congestive heart failure. Acad Emerg Med. 2003;10:544-b-5-b.
30. Levy P, Compton S, Welch R, et al. Treatment of severe decompensated heart failure with high-dose intravenous nitroglycerin: a feasibility and outcome analysis. Ann Emerg Med. 2007;50:144-152.
31. Levy P, Compton S, Dunne R, et al. Need for mechanical ventilation is reduced by the use of high-dose nitroglycerin for patients with acute cardiogenic pulmonary edema: results of an open-label trial. AcadEmerg Med. 2006;13:s107.
32. Publication Committee for the VMAC Investigators. Intravenous nesirit ide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA. 2002;287:1531-1540.
33. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl JMed. 1998;339:321-328.
34. Mills RM, LeJemtel TH, Horton DP, et al. For the Natrecor Study Group. Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo controlled clinical trial. J Am Coll Cardiol. 1999;34:155-162.
35. Colucci WS, Elkayam U, Horton DP, et al. For the Nesiritide Study Group. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompen- sated congestive heart failure. N Engl JMed. 2000;343:246-253.
36. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation. 2005;111:1487-1491.
37. Sackner-Bernstein JD, Kowalski M, Fox M, et al. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA. 2005;293:1900-905.
38. Abraham WT. Nesiritide and mortality risk: individual and pooled nalyses ofrandomized controlled trials. Rev Cardiovasc Med. 2005;6:2.
39. Teerlink J, Massie BM. Nesiritide and worsening of renal function: the mperor's new clothes? Circulation. 2005;111:1459-1461.
40. The Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. Effects of enalapril on ortality in severe congestive heart failure. N Engl J Med. 1987;316:1429 -1435.
41. The SOLVD Investigators. Effect of enalapril on survival in patients ith reduced left ventricular ejection fractions and congestive heart ailure. N Engl J Med. 1991;325:293-302.
42. The SOLVD Investigators. Effect of enalapril on mortality and the evelopment of heart failure in asymptomatic patients with reduced left entricular ejection fractions. N Engl JMed. 1992;327:685-691.
43. Hamilton RJ, Carter WA, Gallagher EJ. Rapid improvement of acute ulmonary edema with sublingual captopril. Acad Emerg Med. 1996;3:205-212.
44. Annane D, Bellissant E, Pussard E, et al. Placebo-controlled, randomized, double-blind study of intravenous enalaprilat efficacy and safety in cute cardiogenic pulmonary edema. Circulation. 1996;94:1316 -1324.
45. Sacchetti A, Ramoska E, Moakes ME, et al. Effect of ED management on CU use in acute pulmonary edema. Am JEmerg Med. 1999;17:571-574.
46. Hoffman JR, Reynolds S. Comparison of nitroglycerin, morphine and urosemide in treatment of presumed pre-hospital pulmonary edema. hest. 1987;92:586-593.
47. Peacock WF, Hollander J, Diercks D, et al. Morphine for acute decompensated heart failure: valuable adjunct or a historical remnant? Acad EmergMed. 2005;12:97b-98b.
48. Collins SP, Mielniczuk LM, Whittingham HA, et al. The use of noninvasive ventilation in emergency department patients with acute cardiogenic pulmonary edema: a systematic review. Ann Emerg Med. 2006;48:260 -269, 9 e1-4.
49. Mehta S, Jay GD, Woolard RH, et al. Randomized, prospective trial of bilevel versus continuous positive airway pressure in acute pulmonary edema. Crit Care Med. 1997;25:620 -628.
50. Philip-Joet FF, Paganelli FF, Dutau HL, et al. Hemodynamic effects of bilevel nasal positive airway pressure ventilation in patients with heart failure. Respiration. 1999;66:136 -143.
51. Levitt MA. A prospective, randomized trial of BiPAP in severe acute congestive heart failure. J Emerg Med. 2001;21:363-369.
52. Nava S, Carbone G, DiBattista N, et al. Noninvasive ventilation in cardiogenic pulmonary edema: a multicenter randomized trial. Am J Respir Crit Care Med. 2003;168:1432-1437.
53. Masip J, Roque M, Sanchez B, et al. Noninvasive ventilation in acute cardiogenic pulmonary edema: systematic review and meta-analysis.JAMA. 2005;294:3124-3130.
54. Cleland JG, Abdellah AT, Khaleva O, et al. Clinical trials update from the European Society of Cardiology Congress 2007:3CPO, ALOFT, PROSPECT and statins for heart failure. Eur JHeart Fail. 2007;9:1070-1073.
55. Pang D, Keenan SP, Cook DJ, et al. The effect of positive pressure airway support on mortality and the need for intubation in cardiogenic pulmonary edema: a systematic review. Chest. 1998;114:1185-1192.
56. Yan AT, Bradley TD, Liu PP. The role of continuous positive airway pressure in the treatment of congestive heart failure. Chest. 2001;120:1675-1685.
57. Masip J, Paez J, Merino M, et al. Risk factors for intubation as a guide for noninvasive ventilation in patients with severe acute cardiogenic pulmonary edema. Intensive Care Med. 2003;29:1921-1928.
58. Gheorghiade M, Mebazaa A. The challenge of acute heart failure syndromes. Am JCardiol. 2005;96(suppl 6A):86G-89G.
59. Kirk JD, Costanza MR. Managing patients with acute decompensated heart failure. Clin Courier. 2006;23:1-14.
60. Gheorghiade M, Abraham WT, Albert NM, et al. For the OPTIMIZE- HF[Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure] Investigators and Coordinators. Systolic blood pressure at admission, clinical characteristics, and outcomes inpatients hospitalized with acute heart failure. JAMA. 2006;296:2217-2226.
61. Filippatos G, Zannad F. An introduction to acute heart failure syndromes: definition and classification. Heart Fail Rev. 2007;12:87-90.
62. Bussmann W, Schupp D. Effect of sublingual nitroglycerin in emergency treatment of severe pulmonary edema. Am J Cardiol. 1978;41931-936.
63. Fonarow GC, Adams KF Jr, Abraham WT, et al. For the ADHERE Scientific Advisory Committee, Study Group, and Investigators. Risk stratification for in-hospital mortality in acutely decompensated heart failure:classification and regression tree analysis. JAMA. 2005;293:572-580.